- Home
- NRIX vs IIM Comparison
NRIX vs IIM Comparison
Compare NRIX & IIM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NRIX
- IIM
- Stock Information
- Founded
- NRIX 2009
- IIM 1993
- Country
- NRIX United States
- IIM United States
- Employees
- NRIX N/A
- IIM N/A
- Industry
- NRIX Biotechnology: Pharmaceutical Preparations
- IIM Investment Managers
- Sector
- NRIX Health Care
- IIM Finance
- Exchange
- NRIX Nasdaq
- IIM Nasdaq
- Market Cap
- NRIX 728.6M
- IIM 588.4M
- IPO Year
- NRIX 2020
- IIM N/A
- Fundamental
- Price
- NRIX $10.69
- IIM $12.63
- Analyst Decision
- NRIX Strong Buy
- IIM
- Analyst Count
- NRIX 14
- IIM 0
- Target Price
- NRIX $29.07
- IIM N/A
- AVG Volume (30 Days)
- NRIX 1.2M
- IIM 122.2K
- Earning Date
- NRIX 10-09-2025
- IIM 01-01-0001
- Dividend Yield
- NRIX N/A
- IIM 4.63%
- EPS Growth
- NRIX N/A
- IIM N/A
- EPS
- NRIX N/A
- IIM 0.02
- Revenue
- NRIX $88,381,000.00
- IIM N/A
- Revenue This Year
- NRIX $74.59
- IIM N/A
- Revenue Next Year
- NRIX N/A
- IIM N/A
- P/E Ratio
- NRIX N/A
- IIM $591.50
- Revenue Growth
- NRIX 41.86
- IIM N/A
- 52 Week Low
- NRIX $8.18
- IIM $9.94
- 52 Week High
- NRIX $29.56
- IIM $12.32
- Technical
- Relative Strength Index (RSI)
- NRIX 63.25
- IIM 64.24
- Support Level
- NRIX $8.20
- IIM $12.39
- Resistance Level
- NRIX $10.23
- IIM $12.76
- Average True Range (ATR)
- NRIX 0.50
- IIM 0.11
- MACD
- NRIX 0.27
- IIM -0.02
- Stochastic Oscillator
- NRIX 99.80
- IIM 70.93
About NRIX Nurix Therapeutics Inc. Common stock
Nurix Therapeutics Inc is a biopharmaceutical company focused on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. The company's pipeline comprises targeted protein degraders of Brutons tyrosine kinase, or BTK, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene-B, or CBL-B, an E3 ligase that regulates T cell activation. Its drug candidate from protein degradation portfolio, NX-2127, is an orally available BTK degrader for the treatment of relapsed or refractory B-cell malignancies.
About IIM Invesco Value Municipal Income Trust
Invesco Value Municipal Income Trust is a diversified, closed-end management investment company. Its investment objective is to provide common shareholders with current income that is exempt from federal income tax.